The company’s shift toward a multi-condition business model is gaining traction, with over 80% of its $13.1 million in contracted annual recurring revenue now tied to platforms managing multiple chronic conditions. Gross margins saw a meaningful lift to 62%, up from 57% in the first quarter, bolstered by the company’s internal AI-driven optimizations and a favorable product mix.

Commercial momentum appears to be building through enterprise partnerships. Recent wins include an expansion with a top-five national health plan—the company's third such deal—and the addition of its fifth Fortune 50 client. DarioHealth is also venturing deeper into provider-backed care, launching an integrated program for GLP-1 oversight. Following the close of the quarter, the firm bolstered its liquidity, raising $22.8 million in net proceeds through a registered direct financing. CEO Erez Raphael maintains that the current infrastructure investments position the company to accelerate revenue growth through the end of 2026 and into 2027.